KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-cash Items (2018 - 2025)

Historic Non-cash Items for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $53.6 million.

  • Adaptive Biotechnologies' Non-cash Items rose 380385.74% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year increase of 380385.74%. This contributed to the annual value of $2.2 million for FY2024, which is 32628.46% up from last year.
  • Adaptive Biotechnologies' Non-cash Items amounted to $53.6 million in Q3 2025, which was up 380385.74% from $29.4 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Non-cash Items high stood at $319.1 million for Q1 2021, and its period low was $108000.0 during Q1 2024.
  • Over the past 5 years, Adaptive Biotechnologies' median Non-cash Items value was $6.7 million (recorded in 2022), while the average stood at $61.9 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Non-cash Items tumbled by 9920.9% in 2024, and later surged by 2437000.0% in 2025.
  • Adaptive Biotechnologies' Non-cash Items (Quarter) stood at $156.1 million in 2021, then crashed by 95.74% to $6.7 million in 2022, then plummeted by 92.39% to $506000.0 in 2023, then soared by 326.28% to $2.2 million in 2024, then surged by 2386.74% to $53.6 million in 2025.
  • Its last three reported values are $53.6 million in Q3 2025, $29.4 million for Q2 2025, and $5.4 million during Q1 2025.